
- /
- Supported exchanges
- / F
- / GIS.F
General Mills Inc (GIS F) stock market data APIs
General Mills Inc Financial Data Overview
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company offers Biktarvy, Genvoya, Descovy, Odefsey, Complera/Eviplera, Symtuza, Truvada, Stribild, and Sunlenca products for the treatment of HIV-1 infection; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Vemlidy, Harvoni, Viread, and Livdelzi for the treatment of liver disease. It also provides Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. In addition, the company's portfolio of market products includes Atripla, Cayston, Descovy for PrEP, Emtriva, Hepcludex, Hepsera, Jyseleca, Sovaldi, Truvada for PrEP, Tybost, Vosevi, and Zydelig. It has collaboration agreements with Arcellx, Inc.; Merck & Co., Inc.; Arcus Biosciences, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Abingworth LLP; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get General Mills Inc data using free add-ons & libraries
Get General Mills Inc Fundamental Data
General Mills Inc Fundamental data includes:
- Net Revenue: 28 754 M
- EBITDA: 13 454 M
- Earnings Per Share: 0
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
What’s included:
- Latest Release: NaN
- EPS/Forecast: NaN
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
General Mills Inc News

Zacks Investment Ideas feature highlights: Gilead Sciences and Johnson & Johnson
For Immediate Release Chicago, IL – March 10, 2025– Today, Zacks Investment Ideas feature highlights Gilead Sciences GILD and Johnson & Johnson JNJ. Buy Gilead Sciences (GILD) Stock at 52-Week H...


Is Gilead Sciences (GILD) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Gilead Sciences (GILD) is a stock that can certainly grab the at...

1 Value Stock with Exciting Potential and 2 to Ignore
1 Value Stock with Exciting Potential and 2 to Ignore Value investing has created more billionaires than any other strategy, like Warren Buffett, who built his fortune by purchasing wonderful busines...

Buy Gilead Sciences (GILD) Stock at 52-Week Highs?
Medical pioneer Gilead Sciences GILD has seen its stock etch out new 52-week highs as the broader market pulled back sharply in recent weeks. Gilead has joined Johnson & Johnson JNJ, and a cluster of ...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.